Stock ORY ORYZON GENOMICS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Revisions Oryzon Genomics S.A.

Equities

ORY

ES0167733015

Market Closed - BME
Other stock markets
 11:35:26 2024-04-26 am EDT 		5-day change 1st Jan Change
2 EUR +0.91% Intraday chart for Oryzon Genomics S.A. +5.60% +5.93%
Apr. 22 Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat CI
Apr. 08 ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer CI

Turnover - Change in analysts' estimates

Earnings Per Share (EPS) - Change in analysts' estimates

EBIT - Change in analysts' estimates

Cash or Net Debt - Change in analysts' estimates

Turnover

Earnings Per Share (EPS)

EBIT

Cash or Net Debt

  1. Stock Market
  2. Equities
  3. ORY Stock
  4. Revisions Oryzon Genomics S.A.